Fundraising FoxAdaptive Phage Therapeutics
Gaithersburg, IL · Founded 2017 · 6 known investors
Find your way into Adaptive Phage Therapeutics
Sign up to see every warm intro you have to Adaptive Phage Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Adaptive Phage Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Aphage develops AI and sensor technologies to identify, track, and classify physical threats across borders, infrastructure, and transportation networks for government and security organizations.
Founders & leadership
Adaptive Phage Therapeutics was founded in 2017 by Gregory L. Merril and Carl R. Merril.
Board
JL
EL
Evan LohBoard director
JJ
Jana JensenBoard director
RL
Raymond L. MartzBoard director
Investors · 6
Hackensack Meridian Health Bear's Denlisted by Hackensack Meridian Health Bear's DenIselin · $250K – $1M
How we know: Hackensack Meridian Health Bear's Den's portfolio page · Not right? Tell us
Maryland TEDCOlisted by Maryland TEDCOColumbia · $500K – $1.5M
How we know: Maryland TEDCO's portfolio page · Not right? Tell us
AMR Action FundreportedBostonvia Martin Heidecker · board
How we know: a partner's Signal profile · board seat on SEC Form D · Not right? Tell us
Deerfield Management CompanyreportedNew York
How we know: a partner's Signal profile · Not right? Tell us
Funding
SEC filings, press & company announcements$45.8M disclosed across 5 of 7 rounds · 2017–2023
- Undisclosed amountSeries BApr 2022Source ↗
▶$12MraisedJun 2023 · 4 investors · BiotechnologyRule 506(b)
▶$12MraisedJun 2023 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jonathan LeffDirector
- Jana JensenDirector
- Carl R. MerrilDirector
- Ian HardyDirector
- Michael OrndorffExecutive Officer
- Gregory L. MerrilExecutive Officer, Director, Promoter
- Jesse GoodmanDirector
- Raymond L. MartzDirector
- Martin HeideckerDirector
- Evan LohDirector
- Subhendu BasuExecutive Officer
- Offering amount
- $30M
- Amount sold
- $12M
- First sale
- May 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$23.3MraisedMay 2021 · 59 investors · BiotechnologyRule 506(b)
▶$23.3MraisedMay 2021 · 59 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Evan LohDirector
- Gregory L. MerrilExecutive Officer, Director, Promoter
- Jonathan LeffDirector
- Jana JensenDirector
- Raymond L. MartzDirector
- Carl R. MerrilExecutive Officer, Director
- Offering amount
- $53.3M
- Amount sold
- $23.3M
- First sale
- May 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$3.6MofferedAug 2020 · PharmaceuticalsRule 506(c)
▶$3.6MofferedAug 2020 · Pharmaceuticals
Rule 506(c)Officers, directors & promoters on the filing
- Subhendu BasuExecutive Officer
- Gregory Louis MerrilExecutive Officer, Director
- Carl MerrilExecutive Officer, Director
- Raymond MartzDirector
- Offering amount
- $3.6M
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06c
▶$2.8MraisedJun 2020 · 12 investors · PharmaceuticalsRule 506(b)
▶$2.8MraisedJun 2020 · 12 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Gregory Louis MerrilExecutive Officer, Director
- Offering amount
- $7M
- Amount sold
- $2.8M
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$7MraisedNov 2019 · 40 investors · PharmaceuticalsRule 506(b)
▶$7MraisedNov 2019 · 40 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Gregory Louis MerrilExecutive Officer, Director
- Raymond MartzDirector
- Carl MerrilExecutive Officer, Director
- Offering amount
- $7M
- Amount sold
- $7M
- First sale
- Jan 2018
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$765KraisedApr 2017 · 10 investors · PharmaceuticalsRule 506(b)
▶$765KraisedApr 2017 · 10 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Gregory MerrilExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $765K
- Minimum investment
- $10K
- First sale
- Feb 2017
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Adaptive Phage Therapeutics do?
- Aphage develops AI and sensor technologies to identify, track, and classify physical threats across borders, infrastructure, and transportation networks for government and security organizations.
- Who founded Adaptive Phage Therapeutics?
- Adaptive Phage Therapeutics was founded by Gregory L. Merril, Carl R. Merril in 2017.
- Who are Adaptive Phage Therapeutics's investors?
- Adaptive Phage Therapeutics's investors include Hackensack Meridian Health Bear's Den, Maryland TEDCO, TEDCO, AMR Action Fund, Deerfield Management Company, Sofinnova Ventures.
- How much funding has Adaptive Phage Therapeutics raised?
- Adaptive Phage Therapeutics has disclosed $45.8M raised across 5 of its 7 known rounds.
- Where is Adaptive Phage Therapeutics headquartered?
- Adaptive Phage Therapeutics is headquartered in Gaithersburg, IL.